目的 探討胞磷膽堿聯(lián)合奧拉西坦治療急性腦梗死的臨床療效。方法 選取2016年1月—2016年12月在濮陽市安陽地區(qū)醫(yī)院進(jìn)行治療的急性腦梗死患者82例，隨機(jī)分為對照組和治療組，每組各41例。對照組患者靜脈注射奧拉西坦注射液，4 g加入生理鹽水250 mL，1次/d。治療組在對照組的基礎(chǔ)上口服胞磷膽堿鈉膠囊，0.2 g/次，3次/d。兩組患者均治療28 d。觀察兩組患者臨床療效，比較治療前后兩組患者神經(jīng)功能缺損評分（NHISS）、日常生活能力量表（ADL）和蒙特利爾認(rèn)知評估量表（MoCA）評分以及不良反應(yīng)情況。結(jié)果 治療后，對照組臨床總有效率為78.05%，顯著低于治療組患者的90.24%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。兩組NHISS評分均顯著降低，MoCA和ADL評分均顯著升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，治療組患者NHISS評分顯著低于對照組，MoCA和ADL評分顯著高于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療期間，對照組不良反應(yīng)發(fā)生率為4.88%，顯著低于治療組患者的17.07%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 胞磷膽堿膠囊聯(lián)合奧拉西坦治療急性腦梗死的臨床療效明顯優(yōu)于單用奧拉西坦，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To discuss the effect of citicoline combined with oxiracetam in treatment of acute cerebral infarction. Methods Patients (82 cases) with acute cerebral infarction in Anyang District Hospital of Puyang from January 2016 to December 2016 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were iv administered with Oxiracetam Injection, 4 g added into normal saline 250 mL, once daily. Patients in the treatment group were po administered with Citicoline Sodium Capsules on the basis of the control group, 0.2 g/time, three times daily. Patients in two groups were treated for 28 d. After treatment, the clinical efficacy was evaluated, and the NHISS, MoCA and ADL scores, adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 78.05%, which was significantly lower than 90.24% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, NHISS score in two groups were significantly decreased, but MoCA and ADL scores were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the NHISS score in the treatment group was significantly lower than that in the control group, but MoCA and ADL scores were significantly higher than that in the control group, with significant difference between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the control group was 4.88%, which was significantly lower than 17.07% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion The clinical efficacy of citicoline combined with oxiracetam in treatment of acute cerebral infarction is significantly better than oxiracetam, which has a certain clinical application value.